Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSB2311 in advanced solid tumors
NCT03463473Phase 1Completed
- Sponsor
- Transcenta
- Start
- Apr 2018
- Primary completion
- Jun 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of MSB2311 in solid tumor (4 arms), sponsored by Transcenta. Primary endpoints: Safety and tolerability of MSB2311 and Maximum tolerated dose or recommended phase 2 dose. Started Apr 2018; status: completed.
02
Drugs
MSB2311
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03463473.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03463473.